Agile Therapeutics
AGRX
AGRX was delisted on the 25th of March, 2024.
19 hedge funds and large institutions have $80.1M invested in Agile Therapeutics in 2014 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 3 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
42% more capital invested
Capital invested by funds: $56.4M → $80.1M (+$23.7M)
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
0% more funds holding
Funds holding: 19 → 19 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Royce & Associates
New York
|
+$801K |
| 2 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$635K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$127K |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$12.7K |
| 5 |
CC
Caxton Corporation
Princeton,
New Jersey
|
+$12.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$189K |
| 2 |
Goldman Sachs
New York
|
-$178K |
| 3 |
LPL Financial
San Diego,
California
|
-$68K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$50.8K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$12.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Morgan Stanley
New York
| – | -$4K | – | – |
|
AGRX Hedge Fund Activity: Q4 2014 in Review
19 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q4 2014, worth a combined $80.1M — up 42% from $56.4M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new AGRX positions and 3 closed out — a net gain of 1 holder — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Royce & Associates, adding an estimated $801K. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $189K sold.
- 19 institutional investors held Agile Therapeutics (AGRX) as of Q4 2014, unchanged from Q3 2014.
- Funds reported $80.1M of Agile Therapeutics stock for Q4 2014, up 42% quarter-over-quarter.
- 4 funds opened new Agile Therapeutics positions in Q4 2014 and 3 closed out, a net change of +1 holder.
- The largest Agile Therapeutics buyer in Q4 2014 was Royce & Associates, an estimated $801K added.
- The largest Agile Therapeutics seller in Q4 2014 was Alyeska Investment Group, an estimated $189K sold.
Based on aggregated 13F filings for Q4 2014.